For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 85,856 | |||
| General and administrative | 33,802 | |||
| Total operating expenses | 119,658 | |||
| Loss from operations | -119,658 | |||
| Interest income | 16,013 | |||
| Change in fair value of contingent value right liability | 0 | |||
| Income tax expense | 0 | |||
| Other expense | -49 | |||
| Total other income (expense), net | 15,964 | |||
| Net loss | -103,694 | |||
| Net unrealized gains (losses) on marketable securities | 279 | |||
| Comprehensive loss | -103,415 | |||
| Basic EPS | -1.83 | |||
| Diluted EPS | -1.83 | |||
| Basic Average Shares | 56,664,226 | |||
| Diluted Average Shares | 56,664,226 | |||
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)